GleamWall
中文EN

GYRE GYRE THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1124105 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.4%
TTM net income YoY-801.1%
TTM EPS YoY-2,500.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin94.1%
Operating margin-20.6%
Net margin-30.1%
FCF margin-20.3%
EBITDA margin-18.8%

Returns

ROE-34.9%
ROA-20.3%
ROIC (approx.)-31.0%
Asset turnover0.68x

Leverage & solvency

Liabilities / assets17.5%
Debt / equity0.00x
Current ratio4.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.63x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$32.93M$29.11M$22.52M$37.20M$32.69M$29.73M$22.06M$27.87M
Cost of revenue$1.95M$2.21M$1.23M$1.74M$1.63M$1.15M$894,000$1.18M
Gross profit$30.99M$26.90M$21.29M$35.45M$28.94M$25.62M$21.16M$26.70M
R&D expense——$6.74M$4.82M$7.80M$8.35M$3.10M$3.71M
SG&A expense$8.95M$7.86M$7.22M$6.70M$6.44M$7.28M$4.96M$5.46M
Operating income-$1.52M-$14.36M-$9.36M$118,000$1.49M-$2.24M$2.27M$597,000
Pretax income-$1.75M-$14.43M-$9.24M$7.65M$2.52M-$1.57M$4.63M$772,000
Income tax$733,000-$164,000$621,000$1.30M$593,000$662,000$901,000$203,000
Net income-$2.48M-$14.27M-$18.58M-$1.32M$1.93M-$2.24M$4.94M$598,000
EBITDA-$1.22M-$13.26M-$8.68M$227,000$2.19M-$1.44M$2.81M$1.06M
EPS (basic)-0.04-0.12-0.10—0.01-0.020.03—
EPS (diluted)-0.04-0.12-0.10—0.01-0.030.00—
Weighted avg. shares (diluted)106.30M100.64M91.34M—103.96M89.20M101.97M—
Banking
Net interest income$588,000$740,000—-$1.00M$954,000$941,000—$346,000
Balance sheet
Cash & equivalents$41.64M$43.29M$37.50M$49.19M$40.40M$36.49M$15.04M$11.81M
Short-term investments$15.77M$14.06M$12.31M$15.36M$19.65M$17.87M$14.85M$14.86M
Receivables$32.66M$27.76M$22.76M$31.08M$25.88M$24.63M$20.15M$19.59M
Inventory$12.22M$11.43M$11.35M$10.17M$8.85M$8.86M$7.88M$6.34M
Current assets$123.40M$122.07M$91.73M$149.36M$98.58M$91.28M$68.45M$64.79M
PP&E, net$27.01M$27.28M$23.57M$27.55M$23.61M$23.40M$23.52M$23.88M
Intangibles$4.40M$4.53M$4.63M$4.73M$4.85M$4.96M$5.08M$273,000
Total assets$201.25M$199.25M$162.01M$219.76M$159.38M$152.65M$129.79M$125.41M
Current liabilities$28.59M$28.66M$19.79M$23.78M$15.91M$16.92M$18.99M$19.52M
Total liabilities$35.18M$34.34M$25.03M$31.40M$21.97M$23.20M$25.49M$27.00M
Shareholders' equity$107.95M$107.93M$101.31M$62.50M$101.92M$92.03M$68.12M$63.32M
Shares outstanding107.07M106.03M91.34M91.31M90.89M90.82M87.64M86.31M
Cash flow statement
Operating cash flow-$3.98M-$16.73M$3.18M-$5.62M-$2.58M$2.09M-$129,000-$2.76M
Capital expenditure$979,000$262,000$178,000$144,000$740,000$256,000$122,000-$65,000
Free cash flow-$4.96M-$16.99M$3.00M-$5.77M-$3.32M$1.83M-$251,000-$2.69M
Investing cash flow$1.73M$9.76M-$3.06M$1.85M$3.19M-$3.04M$1.97M-$2.00M
Financing cash flow$221,000-$8,000$21,000$318,000-$25,000$22.35M$1.34M$964,000
Depreciation & amortization$300,000$1.10M$672,000$109,000$700,000$800,000$535,000$461,000
Stock-based compensation$1.73M$1.83M$2.58M$4.60M$1.33M$1.12M$507,000$567,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.